News | 21 May 2026
Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The company reported free cash flow of Rs. 2,590 Mn for FY26
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated
